Lymphoma Imaging: Nuclear Medicine

Kostakoğlu, Lale; Goldsmith, Stanley J.

doi:10.1007/978-0-387-29346-2_13

Cited by 7 publications

(5 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, 67 Ga accumulation in tumors is mediated by other factors such as anaerobic tumor metabolism, increased tumor perfusion, and vascular permeability. 67 Ga accumulation may require a set of circumstances to be fulfi lled, whereas hypermetabolism as evidenced by increased glycolysis by the tumor cells is suffi cient for 18 F-FDG uptake [14]. The recent investigation of O'Donnell et al [15] showed the relationship between TfR expression and cMyc which is one of the most frequently dysregulated proteins and stimulates proliferation and growth by activating thousands of target genes in malignancies.…”

Section: Discussionmentioning

confidence: 97%

A 18F-FDG-positive, 67Ga-negative, and transferrin receptor expression-negative patient with diffuse large B-cell lymphoma

et al. 2007

View full text Add to dashboard Cite

We recently experienced a case with uveitis suffering from fever of unknown origin suspected of being caused by sarcoidosis. Chest computed tomography showed right supraclavicular, bilateral mediastinal, and right hilar lymphadenopathy, and intensive abnormal uptake of 2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG) was observed on positron emission tomography with 18F-FDG (FDG-PET). On the other hand, 67Ga scintigraphy showed almost no abnormal findings. Histopathological examination revealed the lesion to be a diffuse large B-cell lymphoma (DLBCL), namely, an aggressive non-Hodgkin lymphoma from a right supraclavicular lymph node biopsy specimen. Additional immunohistochemical analysis showed the negative expression of transferrin receptor (TfR) on the formalin-fixed paraffin-embedded specimen. Although DLBCL is generally considered to be a 67Ga-avid tumor, it does not always have a large number of TfRs and that leads to a discrepancy between the 67Ga scintigraphy and FDG-PET findings. FDG-PET should be more appropriate for the initial staging of DLBCL than 67Ga scintigraphy, whereas 67Ga scintigraphy might be able to provide additional information including prognostic factors and to support strategies that target TfR for cancer therapy.

show abstract

Section: Discussionmentioning

confidence: 97%

A 18F-FDG-positive, 67Ga-negative, and transferrin receptor expression-negative patient with diffuse large B-cell lymphoma

et al. 2007

View full text Add to dashboard Cite

show abstract

“…In comparison to 67 Ga scintigraphy which is highly sensitive in high-grade lymphoma detection, 201 Tl is more frequently utilized in imaging low-grade lymphomas [33]. In addition, 201 Tl scintigraphy is more convenient than 67 Ga scintigraphy because it can be performed immediately after injection.…”

Section: Non-fdg Radiopharmaceuticals Used In Clinicmentioning

confidence: 99%

Managing Lymphoma with Non-FDG Radiotracers: Current Clinical and Preclinical Applications

Kong

Ford

Yang

2013

BioMed Research International

View full text Add to dashboard Cite

Nuclear medicine imaging modalities such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) have played a prominent role in lymphoma management. PET with [18F]Fluoro-2-deoxy-D-glucose (FDG) is the most commonly used tool for lymphoma imaging. However, FDG-PET has several limitations that give the false positive or false negative diagnosis of lymphoma. Therefore, development of new radiotracers with higher sensitivity, specificity, and different uptake mechanism is in great demand in the management of lymphoma. This paper reviews non-FDG radiopharmaceuticals that have been applied for PET and SPECT imaging in patients with different types of lymphoma, with attention to diagnosis, staging, therapy response assessment, and surveillance for disease relapse. In addition, we introduce three radiolabeled anti-CD20 antibodies for radioimmunotherapy, which is another important arm for lymphoma treatment and management. Finally, the relatively promising radiotracers that are currently under preclinical development are also discussed in this paper.

show abstract

“…La TEP-FDG est é galement devenue une modalité primordiale pour le suivi thé rapeutique et la dé tection des ré cidives. La TEP-FDG doit ainsi ê tre dé sormais systé matiquement incluse dans les sché mas de prise en charge des lymphomes [37].…”

Section: Lymphomesunclassified